In the pharmaceutical industry, you might hear the terms “FDF” and “API” frequently used in reference to products. We surely understand this type of jargon, but we certainly can see how the general public would feel overwhelmed looking at those kinds of terminology abbreviations.

Eribulin is a chemotherapy drug. Its full name is eribulin mesylate. Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease.

Darolutamide was approved by FDA on Jul 30, 2019, and approved by the EMA on March 27, 2020, the trade name is Nubeqa. The drug was research by Orinon, the on Jun 2014, Bayer got the global development and commercial right in the world. Its molecular conformation is different from Enzalutamide and Apalutamide, and its unique chemical structure enables this drug to inhibit the growth of cancer cells by blocking the function of androgen receptors by blocking nuclear ectopic.

Bosutinib is a Bcr-Abl kinase inhibitor for the treatment of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). Compared to other tyrosine kinase inhibitors, it has a more favourable hematologic toxicity profile. FDA approved on September 4, 2012.

There are so many different drugs ,with different color /shape ( like capsule ,tablet or Infusion) and price . Here we would like to explain , what makes it so different? How is a drug produced?

APIs are generally manufactured through cthat include: Biological and Chemical Processes. How is active pharmaceutical ingredient manufactured? The following is the active pharmaceutical ingredient manufacturing process.

Behind the prosperity of China's API industry, there are many challenges, which make its development encounter difficulties.Objectively speaking, China is currently the world leader in API, and the market is still expanding.

Olmesartan medoxomil is made because the prodrug olmesartan medoxomil that is apace reborn to the pharmacologically active olmesartan.1 it absolutely was developed by Daiichi Sankyo prescription drugs and approved in 2002.

Edoxaban is the first oral anticoagulant on the market in Japan, and it is also the first time in the world. This product can inhibit thrombosis through selective, reversible and direct inhibition of FXa. Its good tolerance, oral absorption and anticoagulant activity have been verified by clinical development.

According to the classification of the World Health Organization (WHO), antibacteriological agents for systemic use are usually divided into 8 subclasses, namely, cefazoles, penicillins, macrolids and linkers, aminoglycosides, quinolones, carbapenems, nitroimidazoles and other anti-infective agents.

Pharmaceutical raw materials are the substances that are used to manufacture wide range of drug formulations, tablets, capsules, injectable etc. The raw material used in the pharmaceutical industry are consisted of three major parts, they are:² API² Excipients² Packaging.

Elagolix (ABT-620) is an oral gonadotropin-releasing hormone antagonist being studied for the treatment of endometriosis, uterine fibroids and PCOS. For the management of moderate to severe pain associated with endometriosis.

Pregabalin, one of the best-selling prescription drugs in the world, is researched and developed by Pfizer, it has been approved by EMA on 6th July 2004, and approved by FDA on 30th Dec 2004. Trade name is LYRICA.

Apixaban is used help prevent strokes or blood clots in people who have atrial fibrillation (a condition in which the heart beats irregularly, increasing the chance of clots forming in the body and possibly causing strokes) that is not caused by heart valve disease.

Icotinib (cas no. 610798-31-7) is a epidermal growth factor receptor tyrosine kinase (EGRF-TKI) inhibitor. It is used for treatment of advanced non-small cell lung cancer (NSCLC).

Gilteritinib Fumarate, developed by Astellas, was approved by the Japanese Pharmaceutical Medical Devices And Devices Integrated Agency (PMDA) on 21 September 2018, subsequently approved by the US Food and Drug Administration (FDA) on 28 November 2018, and by the European Drug Administration (EMA) on 24 October 2019 under the trade name Xospata®.

Ursodeoxycholic acid is a cholelithiant commonly used in the gastroenterology department, and also a cholelithiasis dissolving agent, so it can be used in the treatment of gallstones under normal circumstances, on the premise that the gallbladder has normal contraction function.

Misoprostol is a prostaglandin E1 analogue that causes cervical softening and dilation and uterine contractions. Routes of administration include oral, vaginal, rectal, buccal, and sublingual. Misoprostol, a derivative of prostaglandin E1, can be used in the treatment of duodenal ulcer.

Pharmaceutical intermediates are fine chemical products in the production process from pharmaceutical chemical raw materials to bulk drugs or drugs. The synthesis of chemical drugs depends on high-quality pharmaceutical intermediates. This chemical, which does not require a drug production license, can be produced in ordinary chemical plants and can be used in the synthesis of drugs as long as it reaches certain grades.

Intermediates and additives are common in our daily life, for example, vitamins, disperse dyes, bleaches and emulsifiers are collectively called Intermediates and additives. Today, this article focuses on introducing what intermediates are and what are the differences between them and API.